¡Ya estamos en ! Descubre más

Collegium Pharmaceutical

COLL

Capitalización de mercado USD 755 M

23.19 USD

+0.01

0.04%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

23.19

0.00

0%

1 día

0.04%

5 días

4.74%

1 mes

4.51%

3 meses

-36.06%

6 meses

-29.81%

En lo que va del año

-49.07%

1 año

-30.17%

5 años

10.22%

10 años

32.89%

Acerca de: Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Empleados: 423

Atención médica Fabricantes de medicamentos especializados y genéricos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 20%

Neutral 66.7%

Negativo 13.3%

Zacks Investment Research

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

Zacks Investment Research

New Strong Sell Stocks for October 7th

ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.

New Strong Sell Stocks for October 7th

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, launched Start Talking ADHD, an online resource hub offering practical guides to people living with attention-deficit/hyperactivity disorder (ADHD), and the families who support them.

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:

Collegium to Participate in Upcoming Investor Conferences

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.

Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise.

Collegium Pharmaceutical Q2 Earnings Call Highlights

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™